Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Source: Cancer Network, May 2025
Panelists discuss how monotherapy may still be appropriate for certain patient populations including those with desmoplastic melanoma, solid organ transplants, severe autoimmune disease, and older patients where the toxicity risk of combination therapy may outweigh benefits.
